Nuvation Bio Inc Asset Resilience Ratio
Nuvation Bio Inc asset resilience ratio. Nuvation Bio Inc (NUVB) has an Asset Resilience Ratio of 54.04% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Nuvation Bio Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Nuvation Bio Inc (2019–2025)
Asset resilience ratio of Nuvation Bio Inc from 2019 to 2025. This chart shows how Nuvation Bio Inc's Asset Resilience Ratio has changed over time. Read NUVB total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Nuvation Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Nuvation Bio Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $402.35 Million | 54.04% |
| Total Liquid Assets | $402.35 Million | 54.04% |
Asset Resilience Insights
- Very High Liquidity: Nuvation Bio Inc maintains exceptional liquid asset reserves at 54.04% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nuvation Bio Inc Industry Peers by Asset Resilience Ratio
Compare Nuvation Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Nuvation Bio Inc Asset Resilience Ratio by Year (2019–2025)
Nuvation Bio Inc asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Nuvation Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 61.38% | $365.12 Million | $594.82 Million | -24.99pp |
| 2024-12-31 | 86.38% | $466.97 Million | $540.63 Million | -5.11pp |
| 2023-12-31 | 91.48% | $568.56 Million | $621.48 Million | +8.18pp |
| 2022-12-31 | 83.30% | $559.91 Million | $672.14 Million | +1.75pp |
| 2021-12-31 | 81.55% | $632.97 Million | $776.15 Million | -2.31pp |
| 2020-12-31 | 83.86% | $186.00 Million | $221.79 Million | -11.55pp |
| 2019-12-31 | 95.41% | $115.40 Million | $120.95 Million | -- |
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the ma… Read more